hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The four substrates of this enzyme are 4-hydroxyphenylacetic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen and a proton. Its products are homogentisic acid, oxidised NAD+, and water. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxyphenylacetate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating). Other names in common use include 4-hydroxyphenylacetate 1-hydroxylase, 4-hydroxyphenylacetic 1-hydroxylase, and 4-HPA 1-hydroxylase. This enzyme participates in tyrosine metabolism.
Urea is the parent for a class of chemical compounds that share the same functional group. Namely, such compounds have a carbonyl group attached to two organic amine residues: R1R2N−C(=O)−NR3R4, where R1, R2, R3 and R4 groups are hydrogen (–H), organyl or other groups. Examples include carbamide peroxide, allantoin, and hydantoin. Ureas are closely related to biurets and related in structure to amides, carbamates, carbodiimides, and thiocarbamides.
). Another factor that impacts total CPU time needed by a simulation is the size of the integration timestep. This is the time length between evaluations of the potential. The timestep must be chosen small enough to avoid discretization errors (i.e., smaller than the period related to fastest vibrational frequency in the system). Typical timesteps for classical MD are on the order of 1 femtosecond (10−15 s). This value may be extended by using algorithms such as the SHAKE constraint algorithm, which fix the vibrations of the fastest atoms (e.g., hydrogens) into place. Multiple time scale methods have also been developed, which allow extended times between updates of slower long-range forces. For simulating molecules in a solvent, a choice should be made between an explicit and implicit solvent. Explicit solvent particles (such as the TIP3P, SPC/E and SPC-f water models) must be calculated expensively by the force field, while implicit solvents use a mean-field approach. Using an explicit solvent is computationally expensive, requiring inclusion of roughly ten times more particles in the simulation. But the granularity and viscosity of explicit solvent is essential to reproduce certain properties of the solute molecules. This is especially important to reproduce chemical kinetics. In all kinds of molecular dynamics simulations, the simulation box size must be large enough to avoid boundary condition artifacts.
Sources: en.wikipedia.org
Following diagnosis, the extent of the disease should be established regarding the heart, the lungs, and the muscles/bones (musculoskeletal). Metabolic functions should also be assessed, as lipodystrophy can co-occur with EDMD, by measuring levels of sugar, cholesterol, and triglycerides in the blood. Tests useful for heart evaluation include electrocardiography (EKG), echocardiography (echo), cardiac MRI, and electrophysiology studies. Musculoskeletal function can be assessed by a physical therapist or orthopedist. Regardless of the extent of the disease, cardiac and respiratory complications should be monitored. EKG, holter, and echo are recommended yearly, and additional tests can be indicated depending on heart involvement. Pulmonary function tests (PFTs) are recommended every 2–3 years, or yearly in those with respiratory involvement. Although the root cause of EDMD is not currently treatable, its manifestations and complications can be treated. Heart involvement can be addressed with medications (antiarrhythmics, beta-blockers, and ACE inhibitors), pacemakers, defibrillators, and sometimes heart transplantation. Affecting breathing can be addressed with physical therapy and, later in the disease, mechanical ventilation. Contractures and scoliosis can be addressed with orthopedic surgery. Mobility can be improved with physical therapy, occupational therapy, and mechanical aids (canes, orthoses, wheelchairs).
=== Invasion === The U.S. launched its invasion of Panama on December 20, 1989. Although the killing of the Marine was the ostensible reason for the invasion, the operation had been planned for months before his death. The move was the largest military action by the U.S. since the Vietnam War, and included more than 27,000 soldiers, as well as 300 aircraft. The invasion began with a bombing campaign that targeted Noriega's private vehicles, and the PDF headquarters located in Panama City. Several slums in the middle of the city were destroyed as a result. The day after the invasion, Noriega's deputy Colonel Luis del Cid retreated with some soldiers to the mountains outside David City, after laying mines at the airport. Though this was part of a contingency plan for the invasion, del Cid quickly decided that the Panamanian military was not in a position to fight a guerrilla war against the U.S., and negotiated a surrender. Twenty-three U.S. soldiers were killed in the operation, including two that were killed by friendly fire; 324 soldiers were injured. Casualties among the Panamanian forces were much higher; between 300 and 845. The U.S. government reported between 202 and 250 civilian deaths; Americas Watch estimated 300 civilian deaths; and the United Nations estimated 500 civilian deaths. On December 29, the United Nations General Assembly voted, 75–20 with 40 abstentions, to condemn the invasion as a "flagrant violation of international law". According to a CBS poll, 92% of Panamanian adults supported the U.S. incursion, and 76% wished that U.S.
Complete blood count (CBC) Cation Exchange High-performance liquid chromatography (CE-HPLC): a chromatographic technique used to separate and quantify various normal and abnormal hemoglobin components in blood. Hemoglobin electrophoresis DNA analysis
==== Killing of Israeli civilians ==== The elimination of the State of Israel has been a primary goal for Hezbollah. Hezbollah has been accused of "only [regarding] the Jews living in Israel as Zionists, who should be killed". Throughout the war Hezbollah announced the targeting of civilian homes. On 12 November 2023, Hezbollah fired an anti-tank missile killing an employee of the Israel Electric Corporation who was conducting repair work and injured 13 other Israelis, including six other employees of the Israeli Electric Corporation. The most notable of Hezbollah's attacks on civilians was on 27 July 2024 in the Majdal Shams attack, when Hezbollah fired an Iranian-made Falaq-1 rocket at Majdal Shams, a Druze town in the Golan Heights. The rocket hit a football pitch killing 12 Druze children and injuring at least 42 others. Another attack by Hezbollah resulted in civilian casualties on 9 July 2024, when a rocket struck a couple's car just south of their hometown of Ortal. Additionally, a couple walking their dog in Kiryat Shmona was killed by shrapnel from a Hezbollah rocket on 9 October 2024. On 26 December 2023, a Hezbollah anti-tank missile impacted near a Channel 13 News team while they were interviewing a farmer at Dovev for an article following a prior Hezbollah assault that killed a 56-year-old employee of the Israel Electric Corporation, and injured five workers who were repairing electric lines. Throughout the conflict, Hezbollah fired thousands of inaccurate munitions at Israel and the Golan Heights, killing and injuring civilians and destroying houses.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.